Recent Posts

• Diadem Unveils Novel Findings on Early Alzheimer’s Disease Detection Using p53-Specific Antibody at CTAD 2024
• Diadem Appoints Michael Rasche as Chief Executive Officer
• Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure® Predict Alzheimer’s Disease Prognostic Technology
• Understanding treatment pathways for Alzheimer’s Disease
• Identification and management of Alzheimer’s Disease (AD)Diadem Presents Data at 2023 AAIC® Showing Its AlzoSure® Blood Test Can Identify Patients at High Risk of Significant Cognitive Decline Due to Alzheimer’s DiseaseIdentification and management of Alzheimer’s Disease (AD)

Recent Comments